Arcellx Provides First Quarter 2024 Financial Results
Arcellx, Inc. (NASDAQ: ACLX) reported financial highlights for Q1 2024, with $691.0 million in cash, collaboration revenue of $39.3 million, R&D expenses down by $0.6 million, G&A expenses up by $7.3 million, and a net loss of $7.2 million.
Strong cash position of $691.0 million to fund operations until 2027.
Collaboration revenue increased by $21.4 million due to changes in transaction price with Kite Pharma, Inc.
Net loss of $7.2 million in Q1 2024, although an improvement from $27.3 million in Q1 2023.
General and administrative expenses increased by $7.3 million, driven by higher personnel costs.
Insights
When assessing Arcellx's first quarter financials, a key takeaway is the company's robust cash position. With
Another noteworthy aspect is the substantial increase in collaboration revenue, soaring from
However, the increase in General and Administrative (G&A) expenses by
The reported net loss of
The biotechnology sector is keenly focused on research and development (R&D) as a measure of future potential. Arcellx's slight decrease in R&D expenses, down
Understanding the implications of Arcellx's financial results requires contextualizing the data within the biotech industry. The company's financial stability, marked by substantial cash reserves, combined with its ability to attract and grow major collaborations, like the one with Kite Pharma, is indicative of a promising competitive stance within the industry.
However, it is imperative for stakeholders to consider the broader industry climate, including regulatory hurdles and market reception to new therapies, as these factors can dramatically influence the trajectory of companies like Arcellx. Investors should seek a balance between financial health, R&D progress and the inherent risks associated with the biotech sector.
First Quarter 2024 Financial Highlights
Cash, cash equivalents, and marketable securities:
As of March 31, 2024, Arcellx had cash, cash equivalents, and marketable securities of
Collaboration revenue:
Collaboration revenue were
R&D expenses:
Research and development expenses were
G&A expenses:
General and administrative expenses were
Net income or loss:
Net loss was
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx's lead product candidate, anito-cel, is being developed for the treatment of relapsed or refractory multiple myeloma (rrMM) in a Phase 2 pivotal trial. Anito-cel has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the
Arcellx is also developing its dosable and controllable CAR T therapy, ARC-SparX, through two Phase 1 programs, ACLX-001 for rrMM and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. For more information on Arcellx, please visit www.arcellx.com. Follow Arcellx on X (Twitter) at @arcellx and LinkedIn.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including, without limitation, Arcellx's plans for the research, pre-clinical and clinical development of its product candidates; Arcellx's expectations regarding the potential impact of its product candidates and platforms on patients and cell therapy; and the sufficiency of cash, cash equivalents and marketable securities and Arcellx's ability to fund operations through certain regulatory milestones and timelines. The forward-looking statements contained herein are based upon Arcellx's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including risks that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that Arcellx may file from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
ARCELLX, INC. | |||||
SELECTED CONSOLIDATED BALANCE SHEET DATA | |||||
(in thousands) | |||||
March 31, | December 31, | ||||
2024 |
2023 |
||||
Cash, cash equivalents, and marketable securities | $ |
691,021 |
$ |
729,185 |
|
Total assets |
|
779,695 |
|
825,132 |
|
Total liabilities |
|
283,122 |
|
339,752 |
|
Total stockholders' equity |
|
496,573 |
|
485,380 |
ARCELLX, INC. | |||||||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||||||
(in thousands, except share and per share amounts) | |||||||
Three Months Ended March 31, | |||||||
2024 |
2023 |
||||||
Revenue | $ |
39,256 |
|
$ |
17,912 |
|
|
Operating expenses: | |||||||
Research and development |
|
32,318 |
|
|
32,932 |
|
|
General and administrative |
|
22,748 |
|
|
15,437 |
|
|
Total operating expenses |
|
55,066 |
|
|
48,369 |
|
|
Loss from operations |
|
(15,810 |
) |
|
(30,457 |
) |
|
Other income, net |
|
8,612 |
|
|
3,442 |
|
|
Loss before income taxes |
|
(7,198 |
) |
|
(27,015 |
) |
|
Income tax expense |
|
— |
|
|
329 |
|
|
Net loss |
|
(7,198 |
) |
|
(27,344 |
) |
|
Other comprehensive loss: | |||||||
Unrealized gain (loss) on marketable securities |
|
(1,059 |
) |
|
307 |
|
|
Comprehensive loss | $ |
(8,257 |
) |
$ |
(27,037 |
) |
|
Net loss per share attributable to common stockholders—basic and diluted | $ |
(0.14 |
) |
|
(0.58 |
) |
|
Weighted-average common shares outstanding—basic and diluted |
|
52,757,973 |
|
|
46,769,380 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507588076/en/
Investors:
Myesha Lacy
ir@arcellx.com
510-418-2412
Media:
Andrea Cohen
Sam Brown Inc.
andreacohen@sambrown.com
917-209-7163
Source: Arcellx, Inc.
FAQ
What were Arcellx's cash, cash equivalents, and marketable securities as of March 31, 2024?
What was the collaboration revenue for Arcellx in Q1 2024?
How did R&D expenses change in Q1 2024 compared to Q1 2023?
What was the net loss for Arcellx in Q1 2024?